Trial
NCT04804254
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
AbbVie
Collaborators
—
Condition
B-cell Lymphoma
Intervention
ABBV-623
Why stopped
Strategic considerations
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-03